2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Enrolling by invitation 1 |
Follow CTLA4: new trials by email Literature Review of CTLA4 trials Research Report on CTLA4
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-17 | 2026-10-13 |
| CNCMT：a Multi-center, Prospective, Single-arm Study Neoadjuvant Chemotherapy (NACT), maintenance therapy - Locally Advanced Cervical Cancer, PD1 | Not applicable | Enrolling by invitation | Hubei Cancer Hospital | 20 | 2024-10-08 | 2026-09-18 |
| PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment PD-L1 antibody combined with CTLA-4 antibody - Cholangiocarcinoma, Intrahepatic, PD-L1 | Phase 2 | Active not recruiting | Shanghai Zhongshan Hospital | 40 | 2021-03-26 | 2025-04-16 |
| Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 - Liver Cancer, Lung Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 40 | 2021-01-01 | 2024-06-25 |
| Novel Genetic Disorders of the Immune System PI3KCD, CTLA4 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 500 | 2014-10-22 | 2026-10-16 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1) · Uterine Cervical Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (3) · Central Nervous System Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Adenocarcinoma (1) · Brain Diseases (1) · Breast Diseases (1) · Carcinoma (1) · Central Nervous System Diseases (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1)
Maintenance (1) · Mesothelin (1) · Neoadjuvant Therapy (1) · PSCA protein, human (1) · Pemetrexed (1)
Guangzhou Medical University (1) · Hubei Cancer Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shanghai Zhongshan Hospital (1)
China (4) · United States (1)
Fan Jia, MD & PhD (1) · V. Koneti Rao, M.D. (1) · Zhenfeng Zhang, MD, PhD (1) · Zhenyu Pan, PhD,MD (1)